# Alaunos Therapeutics clinical trials: 37 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 37 trials with Alaunos Therapeutics as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Alaunos Therapeutics: 37 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/alaunos-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 23, 2022 | NCT05292859 | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | Alaunos Therapeutics | Observational | Completed | Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05292859) |
| January 18, 2022 | NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | Alaunos Therapeutics | Phase 1/2 | Terminated | Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05194735) |
| November 18, 2021 | NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors | Alaunos Therapeutics | Observational | Terminated | Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer, Cholangiocarcinoma, Non-small Cell Lung Cancer, Pancreas Cancer | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05124743) |
| July 2, 2019 | NCT04006119 | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | Alaunos Therapeutics | Phase 2 | Terminated | Glioblastoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04006119) |
| September 20, 2018 | NCT03679754 | Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 | Alaunos Therapeutics | Phase 1 | Completed | Glioblastoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03679754) |
| August 17, 2018 | NCT03636477 | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | Alaunos Therapeutics | Phase 1 | Completed | Glioblastoma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03636477) |
| November 6, 2017 | NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | Alaunos Therapeutics | Phase 1/2 | Terminated | Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03330197) |
| April 22, 2015 | NCT02423902 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | Alaunos Therapeutics | Phase 1/2 | Terminated | Metastatic Breast Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02423902) |
| January 1, 2014 | NCT02026271 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | Alaunos Therapeutics | Phase 1 | Completed | Glioblastoma Multiforme, Anaplastic Oligoastrocytoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02026271) |
| October 10, 2012 | NCT01703754 | Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. | Alaunos Therapeutics | Phase 2 | Terminated | Breast Cancer Nos Metastatic Recurrent | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01703754) |
| March 15, 2012 | NCT01555710 | Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell... | Alaunos Therapeutics | Phase 3 | Terminated | Extensive-Stage Small Cell Lung Cancer | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01555710) |
| July 19, 2011 | NCT01397708 | Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma | Alaunos Therapeutics | Phase 1/2 | Completed | Melanoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01397708) |
| April 22, 2011 | NCT01340547 | Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors | Alaunos Therapeutics | Phase 1 | Completed | Advanced Solid Tumors | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01340547) |
| November 16, 2010 | NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | Alaunos Therapeutics | Phase 1 | Completed | Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Testicular Cancer, Thymoma, Ovarian Cancer... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01242072) |
| July 23, 2010 | NCT01168791 | Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma | Alaunos Therapeutics | Phase 3 | Terminated | Soft Tissue Sarcoma | 447 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01168791) |
| June 8, 2010 | NCT01139359 | Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | Alaunos Therapeutics | Phase 1 | Withdrawn | Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01139359) |
| June 8, 2010 | NCT01139346 | Study of Oral Darinaparsin in Patients With Advanced Solid Tumors | Alaunos Therapeutics | Phase 1 | Completed | Advanced Solid Tumors | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01139346) |
| April 30, 2010 | NCT01113970 | Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer | Alaunos Therapeutics | Phase 1 | Terminated | Metastatic Breast Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01113970) |
| December 30, 2008 | NCT00815607 | Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma | Alaunos Therapeutics | Phase 1 | Completed | Melanoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00815607) |
| August 1, 2008 | NCT00726687 | Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors | Alaunos Therapeutics | Phase 1 | Terminated | Advanced Solid Tumors | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00726687) |
| July 18, 2008 | NCT00718484 | A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma | Alaunos Therapeutics | Phase 2 | Terminated | Soft Tissue Sarcoma | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00718484) |
| February 6, 2008 | NCT00608803 | Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors | Alaunos Therapeutics | Phase 1 | Completed | Advanced Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00608803) |
| February 6, 2008 | NCT00607711 | Study of Oral Palifosfamide Tris in Solid Tumors | Alaunos Therapeutics | Phase 1 | Withdrawn | Advanced Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00607711) |
| January 11, 2008 | NCT00592163 | Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas | Alaunos Therapeutics | Phase 1 | Completed | Advanced Solid Tumors, Lymphomas | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00592163) |
| January 11, 2008 | NCT00592046 | A Phase I Trial of ZIO-101 in Hematologic Cancers | Alaunos Therapeutics | Phase 1 | Completed | Acute Leukemia, Chronic Myeloproliferative Disease, Chronic Lymphoproliferative Disease, Multiple Myeloma, Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00592046) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 21 |
| Phase 1/2 | 6 |
| Phase 2 | 6 |
| Phase 3 | 2 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Terminated | 13 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 7 |
| Glioblastoma | 5 |
| Lymphoma | 4 |
| Ovarian Neoplasms | 4 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Multiple Myeloma | 3 |
| Sarcoma | 3 |
| Cholangiocarcinoma | 3 |
| Pancreatic Neoplasms | 3 |
| Breast Neoplasms | 3 |
| Hematologic Neoplasms | 2 |
| Neoplasm Metastasis | 2 |
| Endometrial Neoplasms | 2 |
| Colorectal Neoplasms | 2 |
| Adenocarcinoma of Lung | 2 |
| Melanoma | 2 |
| Small Cell Lung Carcinoma | 2 |
| Bone Marrow Neoplasms | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Lymphoma, T-Cell | 1 |
| Lymphoma, T-Cell, Peripheral | 1 |
| Myeloproliferative Disorders | 1 |
| Leukemia | 1 |
| Anemia, Refractory, with Excess of Blasts | 1 |
| Recurrence | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Russian restaurants in the United States](https://specstream.ai/data/businesses/russian-restaurants/united-states)
- [Australian restaurants in the United States](https://specstream.ai/data/businesses/australian-restaurants/united-states)
- [E-commerce services in the United States](https://specstream.ai/data/businesses/e-commerce-services/united-states)
- [Lawn care companies in the United States](https://specstream.ai/data/businesses/lawn-care-companies/united-states)
- [Sandblasting companies in the United States](https://specstream.ai/data/businesses/sandblasting-companies/united-states)
- [AV equipment rental companies in the United States](https://specstream.ai/data/businesses/av-equipment-rental-companies/united-states)
